37 results about "Colon inflammation" patented technology

The invention belongs to the field of biological medicines, relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for treating ulcerative colitis, and in particular relates to application of polygonatum sibiricum polysaccharides in preparation of medicines for inhibiting release of inflammatory factors, regulating flora imbalance and repairing intestinal mucosal barrier injury. By adjusting the activity of neutrophil Myeloperoxidase (MPO), generation of inflammatory factors IL-6 and TNF-alpha is reduced, expression of an anti-inflammatory factor IL-10 is increased, inflammatory expression is inhibited, colon inflammation is improved by improving intestinal barrier, and potential application of polygonatum sibiricum polysaccharides in treatment of ulcerative colitis is expected to be explored.

The invention provides a seaweed-derived short peptide capable of inhibiting the inflammations of a digestive tract and application thereof. The amino acid main sequences of the short peptide fragments, analogs, derivatives and variants of the short peptide bear 70% or more homogeneity and 90% or more similarity to the main amino acid sequence of the short peptide. The short peptide, a nucleotide,the short peptide fragments, the short peptide analogs, the short peptide derivatives and the short peptide variants are used for preparing drugs or health care products capable of inhibiting the inflammations of the digestive tract and for preparing drugs or health care products capable of treating the inflammations of the digestive tract, i.e., gastritis, treating intestinal inflammation including colonic inflammations and rectal inflammations, and treating mucosal inflammations such as esophagitis. The short peptide of the invention has a clear molecular structure; production technology ismature; the prepared finished product is non-toxic, harmless and free of side effects, has the remarkable feature of capacity of inhibiting the inflammations of the digestive tract and repairing themucosa of the digestive tract, and is an excellent drug for inhibiting the inflammations of the digestive tract.

The invention provides bifidobacterium longum subsp. Longum KLDS K5 capable of preventing and relieving symptoms of colitis, and belongs to the technical field of microorganisms. The invention further provides a preparation method of the bifidobacterium longum subsp. Longum KLDS K5. Experiments show that the bifidobacterium longum provided by the invention can tolerate the human gastrointestinal environment, relieve weight loss in the ulcerative colitis disease period, improve colonic mucosa injury and reduce MPO activity, and inhibit oxidation-related factors through iNOS and COX-2 signal pathways so as to relieve inflammatory bowel diseases; nF-kappa B p65 nuclear transfer is inhibited through a TLR4 / MyD88 / NF-kappa B signal channel, the expression quantity of proinflammatory factors TNF-alpha, IL-1beta, IL-6 and IL-10 in colon is reduced, the transcriptional level of colon tight connection related proteins Claudin-1, ZO-1 and Occludin and mucoprotein MUC2 is up-regulated, the intestinal flora change after DSS induction can be improved in the genus level, and the richness and diversity of the intestinal flora are improved.

The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.

The invention relates to the technical field of food biology, in particular to a preparation method of polyphenol-protein nanoparticles for relieving colitis. The invention provides the preparation method of the polyphenol-protein nanoparticles for relieving colitis. The preparation method comprises the following steps: (1) dissolving protein in a buffer solution, performing stirring at room temperature until the protein is completely hydrated to obtain a protein solution, and storing at 0-5 DEG C for later use; (2) filtering the protein solution through a filter membrane, then performing heat treatment, and then performing cooling to obtain a heat-treated protein solution; (3) dissolving polyphenol in the solution, and performing storing in a dark place; sequentially adding the protein solution subjected to heat treatment at intervals of 0.5-2h to obtain a compound solution; and performing dispersing by using a high-speed disperser, and performing homogenizing for several times to obtain the product. A polyphenol-protein nano-emulsion prepared by the method provided by the invention can protect polyphenol from being influenced by digestion of gastric juice and intestinal juice, so that the polyphenol effectively reaches colon, and the effects of resisting oxidation and inflammation and relieving colitis symptoms are achieved.

A medicament for treating ulcerative colitis relates to medicaments for treating colitis, and is prepared by: selecting the following raw materials by weight: 13-17 g of radix astragali, 13-17 g of radix codonopsis, 13-17 g of bighead atractylodes rhizome, 9-15 g of semen cuscutae, 7-13 g of sophora bud, 9-15 g of sophora flower, 9-15 g of terminalia, 9-15 g of bletillastriata, 25-35 g of charred radix sanguisorbae, 13-17 g of radix paeoniae alba, 9-15 g of pomegranate rind, 9-15 g of Chinese gall, 9-15 g of red halloysite, 7-13 g of banksia rose, 7-13 g of camellia oleifera seeds, 7-13 g of cimicifugafoetida, 3-7 g of cinnamomum cassia and 3-7 g of coptis; cutting into segments or cutting into sheets or grinding into powder, adding 3000-4000 g of water, boiling until one third of water is left, filtering out residues to obtain the medicinal soup. The beneficial effect of the medicament comprise that: by employing oral and clysis, the medicament is capable of simultaneously treating principal and subordinate symptoms, and is fast in drug effect, safe, reliable, and relatively excellent in treatment effect; and 109 examples of clinical experiments show that the effective rate is 98.2%.

The invention relates to the field of medicine and specifically provides a medicament for treating chronic colitis of weakness of spleen and stomach type. The medicament aims to overcome the problem that existing western medicines of glucocorticoids, immunosuppressants and antibiotics have unsatisfactory effect and high recurrence rate, and that Chinese patent medicine has unclear typing on chronic colitis and poor curative effect. The medicament consists of the following components by weight: 15 g of ginseng, 15 g of bighead atractylodes rhizome, 15 g of Poria cocos, 15 g of Astragali Radix, 15 g of raw yam, 10 g of fried hawthorn, 10 g of fried malt, 15 g of fried medicated leaven, 10 g of endothelium corneum gigeriae galli, 10 g of roasted root of kudzu vine, 10 g of rhizoma alismatis, 10 g of honey-fried licorice and 10 g of semen dolichoris. The medicament provided by the invention can treat chronic colitis of weakness of spleen and stomach type, has the functions of invigorating spleen, tonifying qi, harmonizing the stomach, stopping diarrhea, regulating gastrointestinal functions, and regulating intestinal flora, mainly plays the role of adjustment, and has no side effect and definite therapeutic effect.

The invention provides an application of modified nano iron oxide in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The modified nano iron oxide is gamma-Fe2O3 nano particles, positive electricity modified gamma-Fe2O3 nano particles, negative electricity modified gamma-Fe2O3 nano particles or polymer modified gamma-Fe2O3 nano particles. Different modifications are carried out on the nano iron oxide, so that the surfaces of the iron oxide nanoparticles have different charges and potential differences, the purpose of adsorbing different inflammatory proteins in intestinal tracts is achieved, the nano iron oxide adsorbing the inflammatory proteins is discharged out of a body, and the purpose of improving or relieving intestinal diseases is achieved. Experimental results show that the nano iron oxide with different modifications can significantly improve weight loss, disease index increase, colon bleeding, colon shortening, colonic mucosa hyperplasia and colitis response in a dextran sodium sulfate induced inflammatory bowel disease mouse model, so that the inflammatory bowel disease is treated.

The invention relates to a medicament for treating colitis. The medicament is prepared by the following raw materials in parts by weight: 15-25 parts of dried orange peels, 10-20 parts of phellodendron barks, 5-12 parts of ganoderma, 10-20 parts of tokyo violet herbs, 15-25 parts of notoginseng, 5-15 parts of coptis roots, 10-20 parts of Chinese gall, 8-15 parts of ground pine, 5-20 parts of earthworm, 5-15 parts of achyranthes roots, 1-8 parts of codonopsis roots, 10-20 parts of poria, and 5-20 parts of licorice roots. The medicament combines pharmacology and property of the raw medicinal materials, and a lot of researches and repeated clinic treatment tests are carried out in order to develop the medicament; the medicament has the efficacies for invigorating spleen and clearing heat, disinhibiting dampness and relieving pain, and the product can be used for effectively alleviating clinic symptoms of treated patients without side-effects; the product has the advantages of short treatment course, fast effectiveness, and can be used for treating both symptoms and root causes.

The invention discloses microanaerobic bacteria for treating colon inflammation. The microanaerobic bacteria are helicobacter hepaticus. The invention also provides application of the microanaerobic bacteria in preparation of medicines for preventing and / or treating colon inflammation, and application of the microanaerobic bacteria in preparation of medicines for preventing occurrence of colon cancer. The microanaerobic bacteria have the advantages that the function of the helicobacter hepaticus for treating the enteritis inflammation and preventing the occurrence of colon cancers is specifically put forward by the inventor for the first time; the important clinical value and reference meaning are provided for the diagnosis and treatment of colorectal cancer by intestinal flora.

The invention provides a traditional Chinese medicine in forms of suppository, patch and ointment and capable of radically treating hemorrhoid, and the hemorrhoid medicine is prepared from specially-prepared tobacco leaves, sodium chloride, a Chinese herbal medicine with a trivial name of Pazicao and portulaca oleracea. The hemorrhoid medicine has efficacy of repairing material metabolism functions, improving organism immunity, relaxing blood vessels, resolving and releasing toxicity, activating blood and dissipating stasis, diminishing inflammation, relieving pain, stopping bleeding, resolving putridity and promoting tissue regeneration, and the like; and the hemorrhoid medicine has effects of stopping bleeding, relieving pain and dispersing swelling on proctocele bleeding, oedema, purulence and pain caused by various anorectal diseases; and the cure rate is 100%. Additionally, the hemorrhoid ointment also has special curative effect on colitis when being injected into colon inflammation positions. When sodium chloride and portulaca oleracea are removed from the medicine, the obtained medicine has short healing time and amazing curative effect when being attached to various wounds caused by cutters, rusty iron nails and traumatic injuries, and belongs to sovereign remedy for treating open injury caused by outside force. The medicine has auxiliary treatment on beriberi.

The invention discloses a new application of isopentene-based flavonoids compound IAA (isoangustone A) in a drug. The new application disclosed by the invention is as follows: pharmaceutically acceptable salt, ester, solvolyte, stereoisomers, tautomers, prodrugs and a mixture of the salt, the ester, the solvolyte, the stereoisomers, the tautomers and prodrugs are applied in the following aspects: 1) preparing an anti-inflammatory bowel disease drug; 2) preparing a drug for preventing and / or treating colorectal cancer; 3) preparing an eucaryon colorectal cancer cell apoptosis inducer; and 4) preparing an NF-kB (nuclear factor-kappa B) signal inhibitor. The compound IAA can obviously induce the colon cancer cell apoptosis, and inhibit the activity of colon cancer cell and inflammation signals, and also can obviously alleviate the colon inflammation induced by dextran sulfate.

The invention belongs to the field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of medicines for preventing or treating inflammatory bowel diseases. Experimental results of a dextran sodium sulfate (DSS)-induced mouse acute ulcerative colitis model show that the Chinese wolfberry glycopeptide can significantly advance the chronic remission period, significantly alleviate the acute colitis symptom, effectively reduce inflammatory response, and show an obvious anti-inflammatory effect. The experimental results show that the lycium barbarum glycopeptide as a traditional Chinese medicinal material extraction product can be effectively used for preventing and treating the inflammatory bowel disease, has the prospect of being developed into the medicine for preventing and treating the inflammatory bowel disease, provides more treatment choices for clinically preventing or treating the inflammatory bowel disease, and has important social benefits and economic values.

The invention discloses lactobacillus casei L511 capable of inhibiting growth of liver cancer tumors and application of the lactobacillus casei L511. The lactobacillus casei LSC-L511 is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on January 14, 2022, and the preservation number of the lactobacillus casei LSC-L511 is CGMCC (China General Microbiological Culture Collection Center) NO.24309. The lactobacillus casei LSC-L511 is named as Lactobacillus casei LSC-L511. A single strain of the sorafenib has very strong capability of regulating polarization of macrophages, can significantly inhibit the progress of liver cancer, can enhance the treatment effect of sorafenib on liver cancer by inducing ferroptosis of liver cancer cells, and also has multiple functions and applications of relieving colitis, improving intestinal flora structure and short-chain fatty acid level and the like.

The invention belongs to the technical field of nutrient supplementing of dietary foods, and particularly relates to new application of barley leaves. The new application has the advantages that the intestines diseases are treated and / or prevented by the barley leaves through inhibiting the colitis symptoms of the DSS (dextran sulphate sodium)-induced mouse, such as diarrhea and hematochezia; themicroenvironment of intestines is improved by regulating the composition of intestine flora, the proliferation of enterocytes and the increasing of intestinal mucus are promoted, and the intestine barrier function is improved; the obvious promotion function on the application of the barley leaves on market is realized, and a novel intestine dietary intervention path is favorably opened.

The invention relates to application of atrial natriuretic peptide in preparation of a medicine for treating inflammatory bowel diseases. According to the application of the atrial natriuretic peptidein preparation of the medicine for treating inflammatory bowel diseases, the inflammatory bowel diseases comprise ulcerative colitis, Crohn's disease and amorphous colitis. The atrial natriuretic peptide has no adverse effect on normal cells, has no toxic or side effect and can effectively relieve colonic inflammation of colitis and reduce secretion of inflammatory cytokines of colonic tissues.

The invention belongs to the technical field of pharmacology, and discloses application of cubilose in preparation of a medicine for treating ulcerative colitis. The medicine in the application can reduce MPO activity and IL-1beta and TNF-alpha contents in colon tissues of mice, enhance the resistance of organisms to external stimulating factors, alleviate weight loss of the mice due to DSS induction, improve colitis, reduce the level of proinflammatory factors, effectively relieve symptoms and inflammatory indexes of the ulcerative colitis, and provides a new thought for the development of medicines for treating the ulcerative colitis.

The invention belongs to the field of biological medicines, and discloses an application of lactobacillus johnsonii in preparing a medicine for preventing and / or treating inflammatory bowel diseases,and an oral micro-ecological preparation for preventing and / or treating inflammatory bowel diseases. The micro-ecological preparation comprises lactobacillus johnsonii, such as a UMNLJ22 strain. The lactobacillus johnsonii can significantly improve spleen proliferation, colon shortening, colonic mucosa proliferation and colitis reaction in a Citrobacter rodentium-induced inflammatory bowel diseasemouse model, and it is found that the lactobacillus johnsonii can significantly relieve inflammatory bowel diseases of mice, so that the lactobacillus johnsonii is used for development and preparation of drugs for preventing and / or treating inflammatory bowel diseases.

The invention relates to the field of probiotics, in particular to lactobacillus reuteri SXDT-32 and application thereof. The preservation number of the strain is CGMCC (China General Microbiological Culture Collection The strain has a good inhibition effect on escherichia coli and salmonella; the strain can be colonized in an animal body, and has strong tolerance to artificial cholate, artificial gastric acid and artificial intestinal juice; the feed additive can be firmly adhered and colonized in animal intestinal tracts, inhibits growth of pathogenic microorganisms in the intestinal tracts, improves animal intestinal tract immunity, relieves animal colitis, reduces animal diarrhea and death rate, improves animal intestinal tract health, and also can improve animal growth performance.

The invention discloses an application of a radix crotonis crassifolii extract in preparation of a medicine for preventing and / or treating ulcerative colitis. The research finds that the radix crotonis crassifolii extract can obviously relieve symptoms such as colon shortening, colon injury, diarrhea and hematochezia, alleviate tissue inflammatory cell infiltration, and reduce expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at a colon part; and it proves that the radix crotonis crassifolii extract can relieve the ulcerative colitis by protecting the inherent structure of colon tissue and improving the colitis disease, so that a novel natural medicine choice is provided for preventing and / or treating the ulcerative colitis.

The invention relates to the field of traditional Chinese medicines, in particular to a medicament for treating acute and chronic colonitis, which is used for solving the problems of temporary relieving of symptoms, incapability of healing, large side effects and the like existing in the conventional colonitis treating medicament. Chinese medicinal raw materials prepared into active ingredients consist of the following components in parts by weight: 10-20 parts of astragalus, 15-20 parts of Chinese magnoliavine fruit, 10-15 parts of Chinese pulsatilla root, 10-15 parts of hairyvein agrimonia herb and bud, 10-15 parts of weeping forsythia, 5-10 parts of amomum fruit, 5-8 parts of fructus crataegi, 5-8 parts of medicated leaven and 2-5 parts of dried ginger. Cold and warm materials as well as ascending and descending materials supplement each other in a prescription, so that various types of acute and chronic colonitis can be cured in a short period of time, a remarkable curative effect is achieved, the curative rate is up to 90 percent, and relapse after curing is prevented; and moreover, the medicament belongs to a pure Chinese medicinal preparation, is low in cost, is easy to accept by patients, and is worthy of clinical popularization and application.

The invention provides an anthocyanin nanoparticle based on a marine polysaccharide carrier. The marine polysaccharide, food-derived fluorescent nanoparticle, and hyaluronic acid are used as a composite carrier to combine with anthocyanin. The preparation method is: S1, dissolving sodium alginate in phosphoric acid In salt-buffered saline, add EDC and HOBt and food-derived fluorescent nanoparticles in sequence to obtain a fluorescent-alginic acid complex; S2, adding the fluorescent-alginic acid complex to a mixture of DMF and DCM, then adding DIC and DMAP; S3, removing the solvent after adding anthocyanin and the hyaluronic acid; S4, removing unreacted small molecules, and freeze-drying. The present invention can improve the stability of anthocyanin, control the slow release of anthocyanin, has the characteristics of fluorescent tracer, can be used as a fluorescent marker for in vivo imaging of animal tissues and organs, and can also be targeted for delivery to the colon of animals to alleviate the symptoms induced by DSS. Inflammatory damage to the colon.

The invention belongs to the field of biological medicines, and relates to application of glycine in preventing and / or treating inflammatory bowel diseases. Specifically, the invention finds that theglycine can significantly improve weight loss, disease index increase, spleen proliferation, colon shortening, colonic mucosa proliferation and colitis reaction in an inflammatory bowel disease mousemodel induced by Citrobacter rodentium, and further finds that the glycine can significantly alleviate inflammatory bowel disease of a mouse, and therefore, the glycine is used for development and preparation of drugs for preventing and / or treating the inflammatory bowel diseases. The application of the glycine provides a feasible thought for preventing and / or treating the inflammatory bowel diseases from the perspective of nutrition intervention.

The invention discloses a brand new application of a compound shown in a formula 1, namely the compound is used for preparing a medicine for treating an inflammatory bowel disease (IBD) by inhibiting activation of NLRP3 inflammasome and maturation and release of IL-1beta. According to the present invention, the research results show that the compound represented by the formula 1 can inhibit the mouse colitis induced by dextran sulfate sodium salt (DSS), and the application mechanism of the compound represented by the formula 1 mainly comprises that the activation of the NLRP3 inflammasome is inhibited so as to reduce the release of IL-1beta so as to inhibit inflammation; by recording and analyzing the weight loss, the disease activity index (DAI) score and the colon shortening condition of a DSS-induced colitis model mouse and the expression condition of IL-1beta and the like in the mouse colon tissue, the inhibition effect of the compound in the formula 1 on the colitis disease of the DSS-induced mouse colitis model is evaluated.

The invention relates to a method for researching the effect of a microecological preparation on DSS induced colitis mice, which comprises the following steps: randomly dividing 6-week-old healthy male C57BL / 6J mice into a blank control group, a UC model group and a synbiotics intervention group, carrying out gavage treatment on the mice from two weeks before dextran sodium sulfate modeling to the end of modeling and before sampling, wherein the mice of the control group and the model group are subjected to intragastric administration by sterile water every day, and the synbiotics intervention group is subjected to intragastric administration by synbiotics (six probiotics including lactobacillus reuteri, bifidobacterium lactis, bifidobacterium breve, lactobacillus fermentum, lactobacillus rhamnosus and bifidobacterium animalis, maltooligosaccharide GOS, fructo-oligosaccharide FOS and blueberry extract) every day. The mice freely drink a DSS solution, and it is found that the microecological preparation has the following treatment effects on DSS-induced acute UC mice: the synbiotics preparation can improve intestinal flora disorder of the acute UC mice and effectively relieve colitis and intestinal mucosal barrier injury conditions of the acute UC mice.

The invention discloses application of lactobacillus plantarum L168 in assisting sorafenib in treating liver cancer. The invention relates to application of lactobacillus plantarum L168 combined with sorafenib in preparation of a medicine for treating liver cancer, in particular to application of the lactobacillus plantarum L168 combined with sorafenib in preparation of a medicine for treating liver cancer. The single bacterial strain can assist sorafenib in treating liver cancer, significantly inhibit the progress of liver cancer, relieve side effects such as colitis caused by sorafenib, and have multiple functions and uses of improving intestinal flora structure and short-chain fatty acid level.

The invention belongs to the field of biomedicine, and discloses the application of Lactobacillus johnsonii in the preparation of medicaments for preventing and / or treating inflammatory bowel disease, and a method for preventing and / or treating inflammatory bowel disease of oral probiotics comprising Lactobacillus johnsonii strains such as UMNLJ22. In the present invention, Lactobacillus johnsonii can significantly improve spleen hyperplasia, colon shortening, colonic mucosal hyperplasia and colon inflammatory response in the inflammatory bowel disease mouse model induced by Citrobacter rodentium, and it is found that Lactobacillus johnsonii can significantly Alleviate inflammatory bowel disease in mice, so as to be used for the development and preparation of medicaments for preventing and / or treating inflammatory bowel disease.

The invention discloses a microanaerobic bacterium for treating colon inflammation, and the microanaerobic bacterium is Helicobacter hepatica. The present invention also provides the application of the microanaerobic bacteria in the preparation of drugs for preventing and / or treating colon inflammation and the application in the preparation of drugs for preventing colon cancer. In the present invention, the inventors clearly proposed for the first time that Helicobacter helicobacter can treat inflammatory enteritis and prevent colon cancer. It provides important clinical value and reference significance for the intestinal flora to diagnose and treat colorectal cancer.

The invention discloses a preparation method of millet protein, and further discloses a method for preparing millet protein hydrolysate by using the millet protein through hydrolysis, and application of the millet protein hydrolysate to preparation of medicines for treating or improving colitis. The millet protein hydrolysate has the beneficial effects that the millet is a cereal food with homology of medicine and food, the extracted millet protein hydrolysate is used for preparing medicines for treating or improving colitis and intestinal barrier function impairment, can effectively inhibit expression of intestinal proinflammatory cytokines and enhance the intestinal epithelial cell barrier function, and is remarkable in effect, free of toxicity and free of side effects after being taken for a long time.